VX-702 100 mg | ≥98% LKT Laboratories, Inc. p38 MAPK inhibitor. More Information Supplier Page × VX-702
VX-702 25 mg | ≥98% LKT Laboratories, Inc. p38 MAPK inhibitor. More Information Supplier Page × VX-702
VX-702 5 mg | ≥98% LKT Laboratories, Inc. p38 MAPK inhibitor. More Information Supplier Page × VX-702
WZ-4002 100 mg | ≥98% LKT Laboratories, Inc. EGFR (T790M) inhibitor. More Information Supplier Page × WZ-4002
WZ-4002 25 mg | ≥98% LKT Laboratories, Inc. EGFR (T790M) inhibitor. More Information Supplier Page × WZ-4002
RDEA119 5 mg | ≥98% LKT Laboratories, Inc. MEK1/2 inhibitor. More Information Supplier Page × RDEA119
RDEA119 10 mg | ≥98% LKT Laboratories, Inc. MEK1/2 inhibitor. More Information Supplier Page × RDEA119
GSK-1120212 100 mg | ≥98% LKT Laboratories, Inc. MEK1/2 inhibitor. More Information Supplier Page × GSK-1120212
GSK-1120212 25 mg | ≥98% LKT Laboratories, Inc. MEK1/2 inhibitor. More Information Supplier Page × GSK-1120212
GSK-1120212 5 mg | ≥98% LKT Laboratories, Inc. MEK1/2 inhibitor. More Information Supplier Page × GSK-1120212
